M. S. Wicha, S. Liu, and G. Dontu, Cancer stem cells: an old idea-a paradigm shift, Cancer Res, vol.66, pp.1883-1890, 2006.

M. Kakarala and M. S. Wicha, Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy, J Clin Oncol, vol.26, 2008.

M. Dean, T. Fojo, and S. Bates, Tumour stem cells and drug resistance, Nat Rev Cancer, vol.5, pp.275-284, 2005.

C. Ginestier, M. H. Hur, C. , E. Monville, F. Dutcher et al., ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome, Cell Stem Cell, vol.1, pp.555-567, 2007.
URL : https://hal.archives-ouvertes.fr/hal-01431968

C. Ginestier, C. Iovino, F. Wicinski, J. Cervera, and N. , Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature, Cancer Res, vol.69, pp.1302-1313, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01431954

V. J. Möbus, R. Moll, C. D. Gerharz, D. G. Kieback, and O. Merk, Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin, Int J Cancer, vol.77, pp.415-423, 1998.

M. Hassanein, L. Huiart, V. Bourdon, L. Rabayrol, and J. Geneix, Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67, Pathobiology, vol.80, pp.219-227, 2013.

A. Goncalves, E. Charafe-jauffret, F. Bertucci, S. Audebert, and Y. Toiron, Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes, Mol Cell Proteomics, vol.7, pp.1420-1433, 2008.

C. E. Eyler and J. N. Rich, Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis, J Clin Oncol, vol.26, pp.2839-2845, 2008.

J. C. Ame, C. Spenlehauer, and G. De-murcia, The PARP superfamily, Bioessays, vol.26, pp.882-893, 2004.

A. Gonçalves, P. Finetti, R. Sabatier, M. Gilabert, and J. Adelaide, Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis, Breast Cancer Res Treat, vol.127, pp.273-281, 2011.

V. Minckwitz, G. Müller, B. M. Loibl, S. Budczies, J. Hanusch et al., Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy, J Clin Oncol, vol.29, pp.2150-2157, 2011.

H. E. Bryant, N. Schultz, H. D. Thomas, K. M. Parker, and D. Flower, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, vol.434, pp.913-917, 2005.

H. Farmer, N. Mccabe, C. J. Lord, A. Tutt, and D. A. Johnson, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.434, pp.917-921, 2005.

P. C. Fong, D. S. Boss, T. A. Yap, A. Tutt, and P. Wu, Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers, N Engl J Med, vol.361, pp.123-134, 2009.

A. Tutt, M. Robson, J. E. Garber, S. M. Domchek, and M. W. Audeh, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial, The Lancet, vol.376, pp.235-244, 2010.

K. A. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, and A. Robidoux, Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study, Lancet Oncol, vol.12, pp.852-861, 2011.

O. Shaughnessy, J. Schwartzberg, L. Danso, M. R. Miller, K. et al., A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC), J Clin Oncol, vol.29, 2011.

S. Bao, Q. Wu, R. E. Mclendon, Y. Hao, and Q. Shi, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.444, pp.756-760, 2006.

D. J. Barnes, D. Palaiologou, E. Panousopoulou, B. Schultheis, and A. Yong, Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia, Cancer Res, vol.65, pp.8912-8919, 2005.

W. Guo, J. H. Healey, P. A. Meyers, M. Ladanyi, and A. G. Huvos, Mechanisms of Methotrexate Resistance in Osteosarcoma, Clinical Cancer Research, vol.5, pp.621-627, 1999.

M. Dean, ABC transporters, drug resistance, and cancer stem cells, J Mammary Gland Biol Neoplasia, vol.14, pp.3-9, 2009.

R. J. Kelly, R. W. Robey, C. C. Chen, D. Draper, and V. Luchenko, A pharmacodynamic study of the P-glycoprotein antagonist CBT-1 in combination with paclitaxel in solid tumors, Oncologist, vol.17, p.512, 2012.